The platform

Sowa-Omics™: mapping traditional medicine to molecules

A prototype research platform that traces Sowa Rigpa formulas to plants, compounds and biological targets, so the most promising leads can be tested in the lab.

What Sowa-Omics™ is

Sowa-Omics™ is the research platform BBCRI is building. It brings together four things that are usually kept apart: the formulas of Sowa Rigpa, the medicinal plants of Bhutan, modern omics data, and artificial intelligence. The aim is to find promising therapeutic leads in traditional medicine and then test them properly.

Traditional knowledge points us to promising plants and formulas. Omics and computation tell us why they might work. The lab tells us whether they do.

The problem it addresses

Sowa Rigpa holds centuries of human-use experience with medicinal formulas, yet almost none of it has been mapped to molecular targets. That is an untapped discovery pipeline. BBCRI is building the proprietary data, AI and lab partnerships to turn it into licensable leads and products.

A traditional formula may contain many plants, and each plant contains many compounds. Working out which compounds matter, and what they act on in the body, is slow to do by hand. Computational tools can narrow thousands of possibilities to a short list worth testing in a laboratory.

How it works, stage by stage

  1. Biological dataSpecimens, genomes and metabolite profiles from Bhutanese flora. Collection, sequencing and profiling of medicinal plants, stored with collection metadata and the permits that cover them.
  2. Systems understandingNetwork pharmacology across pathways and formulas. We map how a formula's compounds may act on shared pathways, so we can ask why a combination was traditionally used.
  3. Target discoveryBiomarkers and disease targets ranked by evidence. Genes and proteins linked to a condition are ranked using omics data, biomarkers and published literature.
  4. Molecule discoveryDocking and AI screening of natural-product candidates. Docking and machine-learning models screen natural-product compounds against prioritised targets to propose candidates.
  5. ValidationADMET prediction, then wet-lab assays with partners. Predicted absorption and toxicity filter the list. The survivors go to wet-lab assays with partner laboratories.
  6. Therapeutic developmentStandardised extracts and lead compounds. Promising candidates move toward standardised extracts and lead compounds with defined quality and safety data.
  7. Preventive wellnessEvidence-based products rooted in traditional practice. Findings that hold up become evidence-based wellness products that stay faithful to traditional practice.

The data it combines

Modern data layers: Genomics, Transcriptomics, Proteomics, Metabolomics, Systems biology, Bioinformatics, AI / ML, Phenotypic data.

Traditional knowledge layers: Medicinal plants, Traditional formulas, Bhutanese biodiversity.

What exists today

Sowa-Omics™ is a working software prototype. The modules that trace an ingredient to its compounds and on to biological pathways run in an early web version. It is a prototype, not a finished product, and it has not yet produced a laboratory-validated lead. Building the curated database and the laboratory partnerships is the work of the next phases.

Who it is for

Near-term

Platform

AI tools: digitised formulas, compound–target maps, docking and ADMET prediction.

For: Universities, CROs and research teams

Near-term

Research services

Contract work in network pharmacology and in-silico screening, built on the same platform.

For: Institutions, agencies and companies

Mid-term

Evidence-backed products

Standardised, scientifically validated formulations from Himalayan botanicals, sold under our own brand or licensed to partners.

For: Wellness brands and consumers

Long-term

Discovery partnerships

Co-develop natural-product leads with industry partners through research fees, milestone payments and royalties.

For: Pharma and nutraceutical companies

Common questions

Is Sowa-Omics™ a medicine or a treatment?

No. It is a research tool. Nothing that comes out of it is called a therapy until it has been validated, and nothing on this site is medical advice.

Does AI replace laboratory testing?

No. Computation decides what is worth testing first. Whether a candidate works, and whether it is safe, can only be shown in the laboratory and, later, in clinical studies.

Who does the traditional knowledge belong to?

Built around Bhutan's access and benefit-sharing framework and the Nagoya Protocol, crediting knowledge holders. Lawful access is a barrier competitors cannot easily cross.

How does AI drug discovery work in general?

See our plain-language guide: AI drug discovery from medicinal plants.

Can researchers or companies use the platform?

We are opening conversations with research and industry partners now. See how to partner with us.

Start a conversation.

Investors, partners and customers: tell us what you have in mind. We reply to every message.

Email ramesh@bbcri.online Invest or partner